Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 89.37 | 13.70 | 7.23 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 80.37 | 7.86 | 4.36 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 121.36 | 4.25 | 1.92 | |
| Cash | 112.39 | 4.37 | 2.06 | |
| Capex | -298.08 | < 0.005 | < 0.005 | |
| Free Cash Flow | 10.14 | -0.41 | -0.46 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | 43.75 | -0.11 | -0.20 | |
| ROE | 47.66 | -0.12 | -0.23 | |
| ROIC | 43.36 | -0.13 | -0.23 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of IMVT is permitted for members.
5
Growth
The "Growth Entry" for the Focus of IMVT is permitted for members.
6
Leverage & Liquidity